MedShadow Blog

 

2 Books & a Podcast: Facts, Fun & Fallacies

September 19, 2017

A Book for All Ages Thank you, AARP, for this readable and very helpful book on food and drug interactions! Don’t Eat This If You’re Taking That is an unwieldy title, but the book is a handy reference.

Each chapter tackles a drug category, such as blood Continue Reading →

How Pharma Influences Some Patient Advocacy Groups

September 5, 2017
How Pharma Influences Some Patient Advocacy Groups

If there’s a rare disease, there’s likely a patient advocacy group for it. But the way many are funded raises questions about drug companies’ role in them.

Warning: Drug Ads May Cause Confusion

August 29, 2017
Warning: Drug Ads May Cause Confusion

Would allowing pharmaceutical companies to include fewer risks in television and print ads be good for consumers? Members of the MedShadow team weigh in.

Alone and Afraid at 4 AM

August 22, 2017

Laura received a phone call at 4 a.m. It was her 94-year-old mother, gasping that she felt terrible. Mom felt so nauseous, she thought she was about to die. Laura asked if she could breathe. Yes. Could she walk? Yes. Laura was then on her way to Mom.

Laura (not Continue Reading →

Can Diabetics Train to Use Less Glucose-Lowering Medication?

August 15, 2017

Many type 2 diabetics find that glucose-lowering medication is difficult to tolerate. These drugs have multiple potential adverse drug interactions, they are expensive, they cause discomfort and generally lower the quality of life for many. Depending on which class of drug is used, it’s not uncommon to experience Continue Reading →

A New Opioid Deterrent Falls Short

August 8, 2017

I just came back from Washington, having sat on the FDA advisory panel to review the research on IPC Oxy, a new drug application from Intellipharmaceutics.

The Chair of the panel will send a report of the questions raised and comments of the Advisory Committee to the FDA. Ultimately the Continue Reading →

Gone FDA-ing

July 25, 2017

Instead of writing my blog this week, I’ve been preparing for my work at an upcoming FDA hearing on July 25.

I’ll be sitting on an FDA advisory committee reviewing a New Drug Application for an Rexista, an oxycodone extended-release tablet — an opioid painkiller — from Intellipharmaceutics Corp. Continue Reading →